Table 3.
Concentration and reactivity of 7-AABs in all patients and lung nodules group.
| Full cohort | Patients with lung nodules | |||||
|---|---|---|---|---|---|---|
| Patients with malignant diseases (n = 571) | patients with benign diseases (n = 362) | p-value | Malignant lung nodules (n = 459) | Benign lung nodules (n = 285) | p-value | |
| p53 concentration, u/mL, (SD) | 8.87 (15.09) | 3.25 (5.11) | <0.001 | 8.208 (14.65) | 3.316 (5.128) | <0.001 |
| p53 qualitative diagnosis, n (%) | ||||||
| Positive | 116 (20.3) | 18 (5.0) | <0.001 | 92 (20.0) | 9 (3.2) | <0.001 |
| Negative | 455 (79.7) | 344 (95.0) | 357 (80.0) | 276 (96.8) | ||
| PGP9.5 concentration, u/mL, (SD) | 6.17 (10.67) | 3.11 (4.80) | <0.001 | 6.569 (10.44) | 3.025 (3.936) | <0.001 |
| PGP 9.5 qualitative diagnosis, n (%) | ||||||
| Positive | 76 (13.3) | 13 (3.6) | <0.001 | 64 (13.9) | 10 (3.5) | <0.001 |
| Negative | 495 (86.7) | 349 (96.4) | 395 (86.1) | 275 (96.5) | ||
| SOX2 concentration, u/mL, (SD) | 7.46 (12.14) | 3.40 (5.92) | <0.001 | 7.739 (12.67) | 3.127 (4.971) | <0.001 |
| SOX2 qualitative diagnosis, n (%) | ||||||
| Positive | 110 (19.3) | 21 (5.8) | <0.001 | 83 (18.1) | 14 (4.9) | <0.001 |
| Negative | 461 (80.7) | 341 (94.2) | 376 (81.9) | 271 (95.1) | ||
| GACE7 concentration, u/mL, (SD) | 9.59 (18.01) | 4.08 (7.35) | <0.001 | 9.34 (17.36) | 4.405 (8.020) | <0.001 |
| GACE7 qualitative diagnosis, n (%) | ||||||
| Positive | 98 (17.2) | 13 (3.6) | <0.001 | 81 (17.6) | 12 (4.2) | <0.001 |
| Negative | 473 (82.8) | 349 (96.4) | 378 (82.4) | 273 (95.8) | ||
| GBU4-5 concentration, u/mL, (SD) | 3.46 (5.45) | 1.87 (3.57) | <0.001 | 3.542 (5.693) | 1.954 (3.822) | <0.001 |
| GBU4-5 qualitative diagnosis, n (%) | ||||||
| Positive | 97 (16.7) | 19 (5.2) | <0.001 | 78 (17.0) | 17 (6.0) | <0.001 |
| Negative | 476 (83.3) | 343 (94.8) | 381 (83.0) | 268 (94.0) | ||
| MAGEA1 concentration, u/mL,(SD) | 6.36 (12.08) | 3.15 (7.19) | <0.001 | 6.098 (11.44) | 3.334 (7.892) | <0.001 |
| MAGEA1 qualitative diagnosis, n (%) | ||||||
| Positive | 76 (13.3) | 16 (4.4) | <0.001 | 58 (12.6) | 13 (4.6) | <0.001 |
| Negative | 495 (86.7) | 346 (95.6) | 401 (87.4) | 272 (95.4) | ||
| CAGE concentration, u/mL, (SD) | 3.44 (8.06) | 1.75 (2.54) | <0.001 | 3.397 (7.891) | 1.766 (2.653) | <0.001 |
| CAGE qualitative diagnosis, n (%) | ||||||
| Positive | 53 (9.3) | 11 (3.0) | <0.001 | 42 (9.2) | 8(2.8) | <0.001 |
| Negative | 518 (90.7) | 351 (97.0) | 417 (90.8) | 277 (97.2) | ||
| Combined test | ||||||
| Positive, n (%) | 347 (60.7) | 71 (19.6) | <0.001 | 274 (59.7) | 54 (18.9) | <0.001 |
| Negative, n (%) | 224 (39.3) | 291 (80.4) | 185 (40.3) | 231 (81.1) | ||
| AUC | 0.7448 | 0.7476 | ||||